Story perspectives
Opus Genetics' Trial Boosts Vision in LCA5 Patients
10/1/2025
34 5
1 of 1
Story summary
- Opus Genetics' I/II trial of OPGx-LCA5 in Leber congenital amaurosis type 5 (LCA5) shows vision gains for pediatric patients, with improved acuity and retinal sensitivity.
- Adults show sustained vision recovery up to 18 months post-treatment.
- RMAT designation granted to OPGx-LCA5. Opus plans a Q4 2025 meeting with the FDA to discuss next steps, noting independence and quality of life.
